IPA: Koefisien rega marang pendapatan ImmunoPrecise
Will IT infrastructure modernization and laboratory robotization drive growth for ImmunoPrecise Antibodies (IPA)? High barriers to entry provided by the AI platform and phage display confirm the potential, as illustrated by the GURU.Markets platform chart; meanwhile, the value of 5.40 characterizes this median P/S level. Financial stability is based on technology licensing and payments for preclinical research conducted for pharma behemoths.
Rincian analitis perusahaan ImmunoPrecise Antibodies (IPA)
- rega pasar lan target rega analis:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- indikator beban kredit lan likuiditas emiten:
Rasio Kabeh Utang marang Dana Pribadi ImmunoPrecise Antibodies|IPA - Utang jangka dawa marang modal|Utang jangka cendhak marang modal immunoprecise.com|IPA - Utang perusahaan|Rasio utang marang nilai buku ImmunoPrecise|IPA - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak ImmunoPrecise Antibodies|Koefisien jangkoan perantara immunoprecise.com
- data bathi resik lan rasio valuasi:
IPA - Bathi resik|Bathi sing dikarepake ImmunoPrecise Antibodies|IPA - Rasio rega marang bathi|Rasio prakiraan rega marang bathi immunoprecise.com|IPA - Pangali PEG|Nilai perusahaan marang bathi operasional sadurunge panyusutan ImmunoPrecise|IPA - Bathi operasional EBITDA|Bathi resik saben saham sajrone patang kuartal pungkasan ImmunoPrecise Antibodies|IPA - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan immunoprecise.com|IPA - Wutah bathi saben saham ing taun lumaku|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep ImmunoPrecise Antibodies
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:ImmunoPrecise Antibodies Ltd (IPA)
Assessing the operational resilience of ImmunoPrecise Antibodies (IPA) requires an analysis of the company's market capitalization relative to its annual revenue, which determines the premium paid per unit of sales. By examining the P/S ratio trend, an investor can see how the implementation of AI platforms for sustainable antibody synthesis impacts capitalization, helping to identify asset overvaluation risks or potential business undervaluation in a timely manner.
Karo sapa ImmunoPrecise Antibodies saingan
Kapitalisasi marang pendapatan Tempus AI TEM|Multiplikator P/S QGEN (Qiagen)|Koefisien rega marang pendapatan Ionis Pharmaceuticals, Inc. (IONS)|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Corp RNA|CRSP: Multiplikator P/S|Rega marang dodolan genedx.com (WGS)|Kapitalisasi marang pendapatan RARE|BEAM: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S SRPT|Multiplikator P/S Twist Bioscience Corp (TWST)|Rasio rega marang pendapatan 10x Genomics, Inc. TXG|NTLA: Rasio kapitalisasi marang pendapatan|STOK: Kapitalisasi marang pendapatan|BioLife Solutions Inc - Kapitalisasi marang volume dodolan|WVE: Multiplikator P/S|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics Inc) - Multiplikator P/S|Rasio rega marang pendapatan PRME|Rasio rega marang pendapatan Taysha Gene Therapies, Inc. (TSHA)|QURE - Rega marang dodolan|Multiplikator P/S MGTX (MeiraGTx PLC)|RGNX: Rasio kapitalisasi marang pendapatan|Solid Biosciences Inc. - Multiplikator P/S|Koefisien rega marang pendapatan ocugen.com OCGN|PACB: Multiplikator P/S|Rega marang dodolan Benitec Biopharma Inc (BNTC)|Rasio rega marang pendapatan Design Pharma|Rocket Corp (RCKT) - Koefisien rega marang pendapatan|Multiplikator P/S FDMT|Koefisien rega marang pendapatan lexeotx.com|Rasio rega marang pendapatan Korro Bio KRRO|EDIT (Editas Medicine Inc) - Rasio rega marang dodolan|Silence Therapeutics Inc. - Multiplikator P/S|PRQR - Multiplikator P/S|CDXS: Multiplikator P/S|Rasio kapitalisasi marang pendapatan SGMO|Rasio rega marang pendapatan Nautilus Biotechnology, Inc.|Rasio kapitalisasi marang pendapatan MGX (Metagenomi Inc.)|Multiplikator P/S DTIL|Multiplikator P/S generationbio.com (GBIO)|Multiplikator P/S BOLD (Boundless Bio, Inc.)|Koefisien rega marang pendapatan Exicure Inc. (XCUR)|IMNN - Rasio rega marang pendapatan|Phio Pharmaceuticals (PHIO) - Kapitalisasi marang pendapatan|mustangbio.com (MBIO) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan TransCode Therapeutics, Inc.|Kapitalisasi marang pendapatan BNGO|Multiplikator P/S adnas.com|Rasio rega marang pendapatan bluebird bio (BLUE)|Omega Therapeutics Inc - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Singular Genomics Systems Inc OMIC|Regulus (RGLS) - Rega marang dodolan|SYRS - Rasio rega marang pendapatan|Rasio rega marang dodolan TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology Inc. - Rasio kapitalisasi pasar marang pendapatan
